Tag: Policy + Advocacy Updates

CBSA advocates for policies that improve patient access to life-saving novel technologies. This week, CBSA signed on to a letter responding to the long-awaited proposed Transitional Coverage for Emerg...

As the Colorado Prescription Drug Affordability Board (PDAB) begins affordability reviews of the five prescription drugs selected earlier this month, it is reaching out to stakeholders to request thei...

On Friday, August 4, the Colorado Prescription Drug Affordability Board (PDAB) selected five drugs for affordability reviews: Enbrel, Genvoya, Cosentyx, Stelara, and Trikafta. PDAB staff plan to begin...

Congress moved forward with its efforts to address drug shortages, drug pricing, pharmacy benefit managers (PBMs), and transparency ahead of the August recess. This policy post covers the discussion d...

Congress took important action on pandemic preparedness last week, advancing the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization bills in both the Senate and the House ahead of its e...

Drug pricing and affordability continue to be key issues at both the state and federal levels as new legislation is considered and implementation of legislation that has already passed is underway....

Ethylene Oxide (EtO or EO) is a colorless gas used commercially in a wide variety of ways. It is one of the most common and proven ways to sterilize medical devices. EtO’s proven effectiveness means t...

CBSA advocates for policies that allow patients to receive access to critical life-saving novel technologies. We applaud members of Colorado’s Congressional delegation for supporting patient access to...

Weekly Policy Blog: CBSA Advocates for Medicare Coverage of Emerging Technologies CBSA advocates for policies that improve patient access to critical life-saving novel technologies. The bipartisan Ens...

For years, Congress has been urged by a growing coalition of state life sciences associations, patient groups, and other stakeholders, to enact legislation that will modernize the Food & Drug Admi...